Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |
Amgen Inc. patentsThe following is a sampling of recent Amgen Inc. patent applications (USPTO Patent Application #, Patent Title) sorted by month.
August 2011 - Amgen Inc. patents
20110201602 - Protein kinase modulators and method of use
20110195895 - Fgf21 mutants and uses thereof
20110190330 - Spirocyclic gpr40 modulators
July 2011 - Amgen Inc. patents
20110166331 - Il-17 receptor a antigen binding proteins
June 2011 - Amgen Inc. patents
20110151579 - Secreted epithelial stromal-1 molecules and uses thereof
May 2011 - Amgen Inc. patents
20110117053 - Method of modulating fibroblast accumulation or collagen deposition
20110118250 - Beta-secretase modulators and methods of use
20110118252 - Substituted amide derivatives and methods of use
20110104757 - Human anti-b7rp1 neutralizing antibodies
20110105499 - Pyrazolo-pyrazinone compounds and methods of use thereof
20110105498 - Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators and methods of use thereof
April 2011 - Amgen Inc. patents
20110097305 - Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
20110097318 - Solid-state protein formulation
20110097336 - Methods for modulating mannose content of recombinant proteins
20110092504 - Inhibitors of pi3 kinase
20110086834 - Alkynyl alcohols as kinase inhibitors
20110081339 - Methods of using il-17 receptor a antibodies
March 2011 - Amgen Inc. patents
20110052604 - Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
February 2011 - Amgen Inc. patents
20110044986 - Anti-amyloid antibodies and uses thereof
20110045587 - Toxin peptide therapeutic agents
20110033472 - Tumor endothelial marker 5-alpha molecules and uses thereof
20110034487 - Cxcr3 antagonists
January 2011 - Amgen Inc. patents
20110020811 - Host cells comprising alpha 1,2 mannosidase and culture methods thereof
20110021373 - Antibody categorization based on binding characteristics
20110008375 - Uses of myostatin antagonists
20110003755 - Tumor endothelial marker 5-alpha molecules and uses thereof
December 2010 - Amgen Inc. patents
20100331293 - Heterocyclic compounds and their uses
20100331306 - Heterocyclic compounds and their uses
20100331526 - Capture purification processes for proteins expressed in a non-mammalian system
20100331548 - Solid-state form of amg 706 and pharmaceutical compositions thereof
20100323954 - Chimeric polypeptides and uses thereof
20100324047 - Raf kinase modulators and methods of use
20100324269 - Refolding proteins using a chemically controlled redox state
20100316593 - Pharmaceutical formulations
20100317668 - Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
20100311953 - Process for purifying proteins
20100303815 - Method of treating anemia by administering il 1ra
20100305307 - Human monoclonal antibodies to epidermal growth factor receptor
November 2010 - Amgen Inc. patents
20100297668 - Human e3alpha ubiquitin ligase family
20100298229 - Osteoprotegerin
20100298341 - Glycine transporter-1 inhibitors
20100298367 - Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
20100292234 - Triazole fused heteroaryl compounds and methods of use thereof
20100285131 - Fgf21 mutants and uses thereof
20100286060 - Specific binding agents of human angiopoeitin-2
20100279323 - Method for predicting response to epidermal growth factor receptor-directed therapy
20100280008 - Aurora kinase modulators and method of use
October 2010 - Amgen Inc. patents
20100273764 - Inhibitors of pi3 kinase and/or mtor
20100261728 - Trp-m8 receptor ligands and their use in treatments
20100255537 - Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptide and heterodimer thereof
September 2010 - Amgen Inc. patents
20100249102 - Heterotricyclic metalloprotease inhibitors
20100240582 - Peptides and related molecules that modulate nerve growth factor activity
20100240889 - Urea derivatives methods for their manufacture and uses thereof
20100233169 - Methods for treating obesity using fibroblast growth factor-like polypeptides
20100234373 - Bis-aryl amide compounds and methods of use
20100226921 - Methods for treating obesity using fibroblast growth factor-like polypeptides
20100226925 - Homogeneous antibody populations
20100222338 - Beta-secretase modulators and methods of use
August 2010 - Amgen Inc. patents
20100203610 - Methods of treating cell culture media for use in a bioreactor
20100204052 - Protein scaffolds and uses thereof
20100204240 - Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
July 2010 - Amgen Inc. patents
20100183616 - Antibodies against interleukin-1 beta
20100179177 - Heterocyclic compounds and their uses
20100172895 - Human cgrp receptor binding proteins
20100173418 - Polypeptides with reduced susceptibility to oxidation and methods of making
June 2010 - Amgen Inc. patents
20100158908 - Stable polypeptide formulations
20100160283 - Heteroaryl-substituted alkyne compounds and method of use
20100160280 - Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
20100160312 - Substituted pyridone compounds and methods of use
20100137278 - Pyrazine compounds as phosphodiesterase 10 inhibitors
20100137323 - Benzo-fused compounds for use in treating metabolic disorders
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Amgen Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Amgen Inc. with additional patents listed. Browse our Agent directory for other possible listings.
###
FreshPatents.com Support - Terms & Conditions
|
REGISTER now for FREE 
